10d
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
GENFIT’s decision follows the occurrence of a peritonitis case reported as Serious Adverse Event (SAE) in the UNVEIL-IT® clinical trial evaluating VS-01 in patients with ACLF grades 1, 2 or 3a and ...
Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
WCIA Champaign on MSN
Break the social media cycle with this 4-Step Program from Nanette Riendeau!
Living Host Jaclyn Friedlander and licensed psychotherapist Nanette Riendeau, LMFT give you ways to shift your focus when it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback